Down Field Spectroscopy at Ultrahigh Fields

TR&D3：超高场的低场光谱学 项目PI：Walter Witschey博士Ravinder Reddy博士 摘要 本技术研发组件重点研发低场1H磁 共振光谱（DFS）技术来测量几种重要的代谢物（NAD+，谷氨酰胺，PCr， 肌肽和ATP），其不能从常规的高场光谱（UFS）中获得，并且用作 不同疾病的生物标志物。具体而言，它开发了新技术，包括（i）光谱选择性 激发脉冲和空间局部化脉冲序列，具有最佳激发轮廓， （ii）检测和分配DFS代谢物的策略， （iii）能够同时提供UFS和UFS的最佳代谢循环方案 DFS与短回波采集和（iv）后处理流水线集成接收线圈选择，涡流 校正和光谱曲线拟合以及代谢物定量。这些技术发展是由 通过宾夕法尼亚大学内部和分布在美国各地的其他机构的合作和服务项目， 国内外成功完成目标将带来有助于我们改进的技术 了解骨骼肌和心脏的衰老、神经变性、线粒体疾病， 改善这些疾病的诊断，指导靶向治疗的发展， 对这些疗法的疗效进行纵向评价。此外，广泛传播这些技术， 潜在的商业化和下一代生物医学科学家的培训将持续下去， 国家影响。

TR&D3: Downfield Spectroscopy at Ultrahigh Fields Project PIs: Walter Witschey, Ph.D. and Ravinder Reddy, Ph.D. Abstract This technology research and development component focuses on the development of downfield 1H magnetic resonance spectroscopic (DFS) technologies to measure several important metabolites (NAD+, Glutamine, PCr, Carnosine and ATP) that are not accessible from the conventional upfield spectroscopy (UFS), and serve as biomarkers for different diseases. Specifically, it develops novel technologies including (i) Spectral selective excitation pulses and spatially localized pulse sequences with optimal excitation profiles and capable of ultra- short echo acquisition without water suppression (ii) Strategies to detect and assign the DFS metabolites and measure cross-relaxation (iii) Optimal metabolic cycling schemes capable of providing simultaneous UFS and DFS with short echo acquisition and (iv) a post-processing pipeline integrating receive coil selection, eddy current correction and spectral curve fitting and metabolite quantitation. These technological developments are driven by collaborations and service projects from within PENN and from other institutions distributed across the US and abroad. Successful completion of the goals will lead to technologies that contribute to our improved understanding of aging, neurodegeneration, mitochondrial disease in skeletal muscle and heart and, thereby improving diagnosis of these disorders and guiding the development of targeted therapies and enabling longitudinal evaluation of the efficacy of these therapies. Furthermore, wide dissemination of these technologies, potential commercialization, and training of the next generation of biomedical scientists, will have sustained national impact.